Seeking Alpha

Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee...

Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee meeting to review the company's new-drug application for its pancreatitis drug RG1068. The drug developer says it expects the FDA to request additional clinical-trial data.
From other sites
Comments (1)
  • francis williams
    , contributor
    Comments (25) | Send Message
     
    I'm just me, not smart enough to see the above coming. I'm not high on cold showers.
    26 Apr 2012, 11:42 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs